Table 3.
Comparison of baseline characteristics of patients in retrospective and external validation cohort.
| Parameters | Retrospective cohort (%) | External Validation cohort (%) | P |
|---|---|---|---|
| Age | 0.54 | ||
| ≤57 | 139 (51.1%) | 22 (56.4%) | |
| >57 | 133 (48.9%) | 17 (43.6%) | |
| Gender | 0.50 | ||
| Male | 155 (57%) | 20 (51.3%) | |
| Female | 117 (43%) | 19 (48.7%) | |
| Smoking History | 0.12 | ||
| No | 175 (64.3%) | 20 (51.3%) | |
| Yes | 97 (35.7%) | 19 (48.7%) | |
| Anatomical type | 0.16 | ||
| Peripheral | 194 (71.3%) | 32 (82.1%) | |
| Central | 78 (28.7%) | 7 (17.9%) | |
| EGFR | 0.26 | ||
| Wild type | 155 (57%) | 16 (41%) | |
| Sensitive mutation | 81 (29.8%) | 16 (41%) | |
| Resistance mutation | 11 (4%) | 3 (7.7%) | |
| NA | 25 (9.2%) | 4 (10.3%) | |
| Bone metastasis | 0.91 | ||
| No | 170 (62.5%) | 24 (61.5%) | |
| Yes | 102 (37.5%) | 15 (38.5%) | |
| Brain metastasis | 0.15 | ||
| No | 193 (71%) | 32 (82.1%) | |
| Yes | 79 (29%) | 7 (17.9%) | |
| Liver metastasis | 0.15 | ||
| No | 236 (86.8%) | 37 (94.8%) | |
| Yes | 36 (13.2%) | 2 (5.1%) |